Drug Approval | June 16, 2023
Bliss GVS Pharma updates on inspection by USFDA
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Pfizer is likely to show GSK significant competition
UTD2 is the world's first oral epothilone microtubule inhibitor
Subscribe To Our Newsletter & Stay Updated
